MGX PE Ratio & Valuation,Is MGX Overvalued

MGX Relative Valuation

MGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MGX is overvalued; if below, it's undervalued.

Historical Valuation

Metagenomi Inc (MGX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.31. The fair price of Metagenomi Inc (MGX) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：1.61

Fair

-0.64

0.81

EV/EBITDA

Metagenomi Inc. (MGX) has a current EV/EBITDA of 0.81. The 5-year average EV/EBITDA is 0.26. The thresholds are as follows: Strongly Undervalued below -3.78, Undervalued between -3.78 and -1.76, Fairly Valued between 2.29 and -1.76, Overvalued between 2.29 and 4.31, and Strongly Overvalued above 4.31. The current Forward EV/EBITDA of 0.81 falls within the Historic Trend Line -Fairly Valued range.

0.96

EV/EBIT

Metagenomi Inc. (MGX) has a current EV/EBIT of 0.96. The 5-year average EV/EBIT is 0.29. The thresholds are as follows: Strongly Undervalued below -3.54, Undervalued between -3.54 and -1.63, Fairly Valued between 2.20 and -1.63, Overvalued between 2.20 and 4.12, and Strongly Overvalued above 4.12. The current Forward EV/EBIT of 0.96 falls within the Historic Trend Line -Fairly Valued range.

2.77

Metagenomi Inc. (MGX) has a current PS of 2.77. The 5-year average PS is 3.92. The thresholds are as follows: Strongly Undervalued below -0.75, Undervalued between -0.75 and 1.59, Fairly Valued between 6.25 and 1.59, Overvalued between 6.25 and 8.58, and Strongly Overvalued above 8.58. The current Forward PS of 2.77 falls within the Historic Trend Line -Fairly Valued range.

-1.27

P/OCF

Metagenomi Inc. (MGX) has a current P/OCF of -1.27. The 5-year average P/OCF is -1.69. The thresholds are as follows: Strongly Undervalued below -4.05, Undervalued between -4.05 and -2.87, Fairly Valued between -0.52 and -2.87, Overvalued between -0.52 and 0.66, and Strongly Overvalued above 0.66. The current Forward P/OCF of -1.27 falls within the Historic Trend Line -Fairly Valued range.

-0.79

P/FCF

Metagenomi Inc. (MGX) has a current P/FCF of -0.79. The 5-year average P/FCF is -1.37. The thresholds are as follows: Strongly Undervalued below -3.50, Undervalued between -3.50 and -2.43, Fairly Valued between -0.30 and -2.43, Overvalued between -0.30 and 0.76, and Strongly Overvalued above 0.76. The current Forward P/FCF of -0.79 falls within the Historic Trend Line -Fairly Valued range.

Metagenomi Inc (MGX) has a current Price-to-Book (P/B) ratio of 0.34. Compared to its 3-year average P/B ratio of 0.40 , the current P/B ratio is approximately -14.60% higher. Relative to its 5-year average P/B ratio of 0.40, the current P/B ratio is about -14.60% higher. Metagenomi Inc (MGX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -108.99%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -108.99% , the current FCF yield is about -100.00% lower.

0.34

P/B

Median3y

0.40

Median5y

0.40

-149.22

FCF Yield

Median3y

-108.99

Median5y

-108.99

Competitors Valuation Multiple

The average P/S ratio for MGX's competitors is 0.00, providing a benchmark for relative valuation. Metagenomi Inc Corp (MGX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -24.80%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of MGX decreased by 55.40% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -163.04 to -235.51.

The secondary factor is the Revenue Growth, contributed -24.80%to the performance.

Overall, the performance of MGX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-24.80%

11.51M → 8.66M

Revenue Growth

44.45%

-163.04 → -235.51

Margin Expansion

-75.05%

-2.71 → -0.68

P/E Change

-55.40%

3.61 → 1.61

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Metagenomi Inc (MGX) currently overvalued or undervalued?

What is Metagenomi Inc (MGX) fair value?

MGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Metagenomi Inc (MGX) is between NaN to NaN according to relative valuation methord.

How does MGX's valuation metrics compare to the industry average?

What is the current P/B ratio for Metagenomi Inc (MGX) as of Dec 16 2025?

As of Dec 16 2025, Metagenomi Inc (MGX) has a P/B ratio of 0.34. This indicates that the market values MGX at 0.34 times its book value.

What is the current FCF Yield for Metagenomi Inc (MGX) as of Dec 16 2025?

As of Dec 16 2025, Metagenomi Inc (MGX) has a FCF Yield of 0.00%. This means that for every dollar of Metagenomi Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Metagenomi Inc (MGX) as of Dec 16 2025?

As of Dec 16 2025, Metagenomi Inc (MGX) has a Forward P/E ratio of -0.64. This means the market is willing to pay $-0.64 for every dollar of Metagenomi Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Metagenomi Inc (MGX) as of Dec 16 2025?

As of Dec 16 2025, Metagenomi Inc (MGX) has a Forward P/S ratio of 0.00. This means the market is valuing MGX at $0.00 for every dollar of expected revenue over the next 12 months.

MGX Valuation